Related references
Note: Only part of the references are listed.Discovery of adamantane based highly potent HDAC inhibitors
Balasubramanian Gopalan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function
Marinus R. Heideman et al.
BLOOD (2013)
A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance
Fabio Santoro et al.
BLOOD (2013)
A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors
M. New et al.
CELL DEATH AND DIFFERENTIATION (2013)
Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial
Madeleine Duvic et al.
EUROPEAN JOURNAL OF CANCER (2013)
Targeting class I histone deacetylases in cancer therapy
Genevieve P. Delcuve et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2013)
Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials
Tianzhu Qiu et al.
FUTURE ONCOLOGY (2013)
HDAC11 is a novel drug target in carcinomas
Hedwig E. Deubzer et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group
Mercedes Lobera et al.
NATURE CHEMICAL BIOLOGY (2013)
Discovering the Binding Modes of Natural Products with Histone Deacetylase 1
Lei Zhang et al.
MEDICINAL CHEMISTRY (2013)
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses
J. E. Bolden et al.
CELL DEATH & DISEASE (2013)
Expansion of the Lysine Acylation Landscape
Christian A. Olsen
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2012)
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Loredana Santo et al.
BLOOD (2012)
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas
Mei Dong et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
Udai Banerji et al.
CLINICAL CANCER RESEARCH (2012)
HDAC Inhibitors Augmented Cell Migration and Metastasis through Induction of PKCs Leading to Identification of Low Toxicity Modalities for Combination Cancer Therapy
Kuen-Tyng Lin et al.
CLINICAL CANCER RESEARCH (2012)
Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed
Berkley E. Gryder et al.
FUTURE MEDICINAL CHEMISTRY (2012)
HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins
Kwang Hwa Jung et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2012)
Rationale for the Development of 2-Aminobenzamide Histone Deacetylase Inhibitors as Therapeutics for Friedreich Ataxia
Elisabetta Soragni et al.
JOURNAL OF CHILD NEUROLOGY (2012)
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
HDAC inhibitor-based therapies: Can we interpret the code?
Maria New et al.
MOLECULAR ONCOLOGY (2012)
Trials with 'epigenetic' drugs: An update
Angela Nebbioso et al.
MOLECULAR ONCOLOGY (2012)
HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle
Matthew A. Deardorff et al.
NATURE (2012)
Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages
Xuefen Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies
W. P. Yong et al.
ANNALS OF ONCOLOGY (2011)
Safety and Efficacy of an Oral Histone Deacetylase Inhibitor in Systemic-Onset Juvenile Idiopathic Arthritis
Jelena Vojinovic et al.
ARTHRITIS AND RHEUMATISM (2011)
Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours
A. R. A. Razak et al.
BRITISH JOURNAL OF CANCER (2011)
Identification of 67 Histone Marks and Histone Lysine Crotonylation as a New Type of Histone Modification
Minjia Tan et al.
CELL (2011)
Histone Deacetylases 9 and 10 Are Required for Homologous Recombination
Shweta Kotian et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors
Giuseppe Giaccone et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
Teru Hideshima et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
Anas Younes et al.
LANCET ONCOLOGY (2011)
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung
Yoshihiro Minamiya et al.
LUNG CANCER (2011)
Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes
Marcus Bantscheff et al.
NATURE BIOTECHNOLOGY (2011)
Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model
Chiranjeevi Sandi et al.
NEUROBIOLOGY OF DISEASE (2011)
Frequent Alterations and Epigenetic Silencing of Differentiation Pathway Genes in Structurally Rearranged Liposarcomas
Barry S. Taylor et al.
CANCER DISCOVERY (2011)
Drug Targeting to Monocytes and Macrophages Using Esterase-Sensitive Chemical Motifs
Lindsey A. Needham et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides
Jerome C. Bressi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Differential expression of HDAC3, HDAC7 and HDAC9 is associated with prognosis and survival in childhood acute lymphoblastic leukaemia
Daniel Antunes Moreno et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Hdac3 Is Essential for the Maintenance of Chromatin Structure and Genome Stability
Srividya Bhaskara et al.
CANCER CELL (2010)
HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth
Till Milde et al.
CLINICAL CANCER RESEARCH (2010)
Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis
Roel H. Wilting et al.
EMBO JOURNAL (2010)
Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma
Heiner Adams et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression
Teppei Yamaguchi et al.
GENES & DEVELOPMENT (2010)
Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma
Sean J. Whittaker et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Histone Deacetylase 7 and FoxA1 in Estrogen-Mediated Repression of RPRM
Simeen Malik et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
Chemical phylogenetics of histone deacetylases
James E. Bradner et al.
NATURE CHEMICAL BIOLOGY (2010)
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
Omar Khan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy
Leigh Ellis et al.
BLOOD (2009)
Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome on HDAC Inhibitor-Induced Apoptosis
Susan Fotheringham et al.
CANCER CELL (2009)
Histone deacetylase inhibitors and genomic instability
Gregory Eot-Houllier et al.
CANCER LETTERS (2009)
Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
Ina Oehme et al.
CLINICAL CANCER RESEARCH (2009)
A phosphorylation-acetylation switch regulates STAT1 signaling
Oliver H. Kraemer et al.
GENES & DEVELOPMENT (2009)
Acetylation of non-histone proteins modulates cellular signalling at multiple levels
Stephanie Spange et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
HDAC4 Represses Vascular Endothelial Growth Factor Expression in Chondrosarcoma by Modulating RUNX2 Activity
Xiaojuan Sun et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard L. Piekarz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism
D. Mottet et al.
ONCOGENE (2009)
Genetic dissection of histone deacetylase requirement in tumor cells
Michael Haberland et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors
Jung-Hyun Park et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
W. Weichert et al.
BRITISH JOURNAL OF CANCER (2008)
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma
Valeria R. Fantin et al.
CANCER RESEARCH (2008)
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas
Lia Gore et al.
CLINICAL CANCER RESEARCH (2008)
Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay
Claire Bonfils et al.
CLINICAL CANCER RESEARCH (2008)
Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer:: Specific role of class I histone deacetylases in vitro and in vivo
Wilko Weichert et al.
CLINICAL CANCER RESEARCH (2008)
Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma
L. Marquard et al.
HISTOPATHOLOGY (2008)
Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain
Matthew J. Bottomley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity
Anja Schuetz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21
Andrew J. Wilson et al.
MOLECULAR BIOLOGY OF THE CELL (2008)
Destabilization of ERBB2 transcripts by targeting 3'untranslated region messenger RNA associated HuR and histone deacetylase-6
Gary K. Scott et al.
MOLECULAR CANCER RESEARCH (2008)
Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin
Andrea Newbold et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer:: a retrospective analysis
Wilko Weichert et al.
LANCET ONCOLOGY (2008)
A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas
S. Balasubramanian et al.
LEUKEMIA (2008)
Multicenter phase II trial of the historic deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma
Axel Hauschild et al.
MELANOMA RESEARCH (2008)
Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator
Sai Murali Krishna Pulukuri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Deacetylase inhibition promotes the generation and function of regulatory T cells
Ran Tao et al.
NATURE MEDICINE (2007)
Histone deacetylases and cancer
M. A. Glozak et al.
ONCOGENE (2007)
Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
Elise A. Olsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Role for histone deacetylase 1 in human tumor cell proliferation
Silvia Senese et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma
R. K. Lindemann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Histone deacetylase 2 modulates p53 transcriptional activities through regulation of p53-DNA binding activity
Kelly Lynn Harms et al.
CANCER RESEARCH (2007)
Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma, (CTCL)
Madeleine Duvic et al.
BLOOD (2007)
Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma
Tatsuya Rikimaru et al.
ONCOLOGY (2007)
Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARα as a component of the N-CoR co-repressor complex to repress transcription in vivo
Akihide Atsumi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Histone deacetylase 3 (HDAC3) and other class IHDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer
AJ Wilson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition
S Ropero et al.
NATURE GENETICS (2006)
Differential expression of selected histone modifier genes in human solid cancers
Hilal Ozdag et al.
BMC GENOMICS (2006)
Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis
Y Zhang et al.
CELL DEATH AND DIFFERENTIATION (2006)
Anticancer activities of histone deacetylase inhibitors
Jessica E. Bolden et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Acetylation and deacetylation of non-histone proteins
MA Glozak et al.
GENE (2005)
Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast
ZH Zhang et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90 - A novel basis for antileukemia activity of histone deacetylase inhibitors
P Bali et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer
S Saji et al.
ONCOGENE (2005)
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
T Hideshima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma
QC Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor
JJ Kovacs et al.
MOLECULAR CELL (2005)
Increased expression of historic deacetylase 2 is found in human gastric cancer
J Song et al.
APMIS (2005)
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer
MF Fraga et al.
NATURE GENETICS (2005)
Histone deacetylase-1 and-3 protein expression in human breast cancer:: a tissue microarray analysis
CA Krusche et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas
H Duan et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
A Nebbioso et al.
NATURE MEDICINE (2005)
Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway
A Insinga et al.
NATURE MEDICINE (2005)
Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid
CM Reilly et al.
JOURNAL OF IMMUNOLOGY (2004)
Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases
JR Somoza et al.
STRUCTURE (2004)
Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients
H Osada et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor
A Vannini et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
HDAC6 expression is correlated with better survival in breast cancer
ZH Zhang et al.
CLINICAL CANCER RESEARCH (2004)
ONCOMINE: A cancer microarray database and integrated data-mining platform
DR Rhodes et al.
NEOPLASIA (2004)
The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress
Y Kawaguchi et al.
CELL (2003)
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation
SJ Haggarty et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family
L Gao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
HDAC6 is a microtubule-associated deacetylase
C Hubbert et al.
NATURE (2002)
Enzymatic activity associated with class IIHDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR
W Fischle et al.
MOLECULAR CELL (2002)
The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3
MG Guenther et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins
SW Hiebert et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Deacetylation of p53 modulates its effect on cell growth and apoptosis
JY Luo et al.
NATURE (2000)
Share Paper
